Abstract 1683P
Background
Myeloproliferative neoplasms (MPN) are chronic haematological malignancies including myelofibrosis (MF), polycythaemia vera (PV) and essential thrombocythemia (ET). People with MPN require proper education to confidently manage their health at home. If they develop high levels of self-care confidence, they might be more capable of performing self-care behaviours and improving their quality of life. This study aims to preliminary assess the self-care confidence of MPN patients and its association with their quality of life.
Methods
This is a descriptive cross-sectional study conducted by the Italian Association of MPN Patients (AIPAMM). Preliminary data from 9 haematology centres in Italy were analysed. During their outpatient visit, patients with MPN were given a paper-and-pencil questionnaire to measure self-care confidence using the Self-Care Confidence Scale, symptom burden using the MPN-SAF TSS, and quality of life using the EORTC QLQ-C30.
Results
The study included 292 adult patients with MPN (55% male; mean age = 60 years ± 14). They were diagnosed with MF (42%), ET (30%), or PV (28%). The most burdensome symptoms were fatigue, problems with concentration, abdominal discomfort, and inactivity. Participants rated their overall quality of life as 69.5 ± 22.8 (range 0-100). The mean level of self-care confidence was 77.4 ± 16.3 (range 0-100). We found that a higher level of self-care confidence is associated with lower symptom burden (r = -.24; p <. 001) and greater quality of life (r =. 30; p <. 001).
Conclusions
This study revealed that enhancing self-care confidence in MPN patients can decrease their symptom burden and improve their quality of life. Health professionals should educate and support people living with MPN in performing self-care behaviours to enhance their ability to manage their health at home and their level of confidence. In particular, patients should be empowered to utilize suitable strategies to address fatigue and problems with concentration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1636P - Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Presenter: Renée Bultijnck
Session: Poster session 11
1637P - Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Presenter: Neeraj Agarwal
Session: Poster session 11
1638P - Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Presenter: Neal Shore
Session: Poster session 11
1639P - Self efficacy in people with prostate cancer in the UK: A large, digital survey
Presenter: Joe O'Sullivan
Session: Poster session 11
1640P - Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
Presenter: Ziyun Wang
Session: Poster session 11
1641P - Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Presenter: Christos Kyriakopoulos
Session: Poster session 11
1642P - Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
Presenter: Charles Vauchier
Session: Poster session 11
1643P - Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Presenter: Bicky Thapa
Session: Poster session 11
1644P - PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Lana Broer
Session: Poster session 11
1645P - Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Presenter: Marta Garcia De Herreros
Session: Poster session 11